Bridgefront Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Bridgefront Capital’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-18,377	Closed	-$337K	–	593
2024 Q4	$337K	Buy	18,377 +2,740	+18%	+$44.2K	0.11%	326
2024 Q3	$240K	Buy	+15,637	New	+$261K	0.09%	401
2022 Q2	–	Sell	-9,266	Closed	-$224K	–	289
2022 Q1	$224K	Buy	+9,266	New	+$224K	0.28%	179

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Bridgefront Capital's ACAD Position: Q1 2025 in Review

Bridgefront Capital sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 18,377 shares — an estimated $337K sold.

Bridgefront Capital first reported a position in ACAD in Q1 2022 and held it in 3 quarters. The position peaked at $337K in Q4 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

Bridgefront Capital reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Bridgefront Capital sold 18,377 Acadia Pharmaceuticals shares in Q1 2025, an estimated $337K.
Bridgefront Capital first reported a position in Acadia Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Bridgefront Capital's Acadia Pharmaceuticals position peaked at $337K in Q4 2024.
320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Bridgefront Capital's 13F filing for Q1 2025, filed 15 May 2025.